Ro pauses advertising of weight loss drug Wegovy amid shortages
Telehealth company Ro has paused advertising of the obesity drug Wegovy as the drug suffers shortages, a reversal in aggressive promotional efforts by the provider that involved splashy ads in subway stations.
Novo Nordisk, the maker of Wegovy, said last month it would limit its starting doses for new patients and pause advertising of the drug to avoid stimulating further demand. “Following Novo’s lead, we’ve paused key promotional efforts (including all TV),” Zachariah Reitano, chief executive of Ro, wrote Monday in a post on its site. “We’re reassessing other promotional plans as well.”
Read Original Article: Ro pauses advertising of weight loss drug Wegovy amid shortages »
